$132.04
-3.22-2.38%
Last update: Nov 6, 4:00 PM
Protagonist Therapeutics Inc (PTGX) Stock Price, Quote, News & History
PTGXNASDAQ
FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.
You can purchase shares of Protagonist Therapeutics (NASDAQ:PTGX) through any online brokerage.
Other companies in Protagonist Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Protagonist Therapeutics has a consensus price target of $140.68.
The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $132.04 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Protagonist Therapeutics.
Protagonist Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Protagonist Therapeutics.
Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology,...
